Company news
Immunome, Inc. (NASDAQ:IMNM) news
Immunome, Inc. news releases on 6ix. Latest, May 20, 2024: Immunome Announces Completion of Purchase of Assets from Atreca
Press releases — page 2
Immunome Announces Completion of Purchase of Assets from Atreca
May 19, 2024
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 16, 2024
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Immunome to Present at 2024 Bank of America Healthcare Conference
May 7, 2024
Immunome Appoints Kinney Horn as Chief Business Officer
May 1, 2024
Immunome Appoints Sandra M. Swain to Board of Directors
April 24, 2024
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 4, 2024
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 27, 2024
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 25, 2024
Immunome to Participate in the Leerink Partners Global Biopharma Conference
March 6, 2024
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
February 29, 2024
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 19, 2024
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 19, 2024
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 15, 2024
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 5, 2024
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 5, 2024
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 4, 2024
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
January 7, 2024
Immunome Appoints Phil Roberts as Chief Technical Officer
January 3, 2024
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Immunome Appoints Carol A. Schafer to Board of Directors
January 1, 2024
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
December 25, 2023
Immunome to Present at the Stifel 2023 Healthcare Conference
November 9, 2023
Immunome Reports Third Quarter 2023 Financial Results
November 8, 2023
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
November 7, 2023
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
October 18, 2023
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
October 2, 2023
Immunome Reports Second Quarter 2023 Financial Results
August 8, 2023
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
June 28, 2023
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 22, 2023
Immunome Reports First Quarter 2023 Financial Results
May 4, 2023
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
Immunome to Present at 13th Annual World ADC London Conference
March 8, 2023
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
February 7, 2023
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 5, 2023
Immunome Reports Third Quarter 2022 Financial Results
November 13, 2022
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 8, 2022
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
August 22, 2022
Immunome Reports Second Quarter 2022 Financial Results
August 4, 2022
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
July 5, 2022
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
June 8, 2022
Immunome to Present at the Jefferies Healthcare Conference
June 1, 2022
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
May 22, 2022
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
May 18, 2022
Immunome Reports First Quarter 2022 Financial Results
May 11, 2022
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
March 27, 2022
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
March 10, 2022
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
February 7, 2022
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
January 9, 2022
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
December 6, 2021